Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA9159 nasal spray in healthy Chinese adults
NCT07345442Phase 1Completed
- Sponsor
- Anhui Palo Alto Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pa9159 in allergic rhinitis (AR) (12 arms), sponsored by Anhui Palo Alto Pharmaceuticals. Primary endpoint: Adverse Events. Started Mar 2025; status: completed.
02
Drugs
pa9159
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07345442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345442.